Triferic Avnu is owned by Rockwell Medical Inc.
Triferic Avnu contains Ferric Pyrophosphate Citrate.
Triferic Avnu has a total of 1 drug patent out of which 0 drug patents have expired.
Triferic Avnu was authorised for market use on 27 March, 2020.
Triferic Avnu is available in solution;intravenous dosage forms.
Triferic Avnu can be used as method of iron administration to treat patients in need of iron replacement therapy.
The generics of Triferic Avnu are possible to be released after 17 April, 2029.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US7816404||ROCKWELL MEDICAL INC||Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions|| |
(6 years from now)
Market Authorisation Date: 27 March, 2020
Treatment: Method of iron administration to treat patients in need of iron replacement therapy
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic